Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH)
about
Human cannabinoid pharmacokineticsStudies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques.Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH).Self-administration of cannabinoids by experimental animals and human marijuana smokers.Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THCPharmacokinetic and pharmacodynamic profile of supratherapeutic oral doses of Δ(9) -THC in cannabis users.Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administrationSimultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis.A literature review to assess the reliability and validity of measures appropriate for use in research to evaluate the efficacy of a brief harm reduction strategy in reducing cannabis use among people with schizophrenia in acute inpatient settings.In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis.Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?Recent advances in LC-MS/MS analysis of Δ(9)-tetrahydrocannabinol and its metabolites in biological matrices.Driving Under the Influence of Marijuana Versus Driving and Dying Under the Influence of Marijuana: A Comparison of Blood Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol and OthDelta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC.Comparison between self-report of cannabis use and toxicological detection of THC/THCCOOH in blood and THC in oral fluid in drivers in a roadside survey.Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomizeUltra-high performance liquid chromatography tandem mass-spectrometry for simple and simultaneous quantification of cannabinoids.Pediatric Death Due to Myocarditis After Exposure to Cannabis.Detection of Delta9-tetrahydrocannabinolic acid A in human urine and blood serum by LC-MS/MS.Pharmacokinetics of 11-nor-9-Carboxy-Δ9-Tetrahydrocannabinol (CTHC) After Intravenous Administration of CTHC in Healthy Human SubjectsToxicology of Specific Substances
P2860
Q24652736-75053641-7DC9-44F5-89B0-60C58B1087CBQ35001064-A4983C95-CA18-4EB5-8B3D-CBA7CA03D2AEQ35175994-DED54C80-7747-45B2-AA2F-13E1D1F7DFD8Q35391358-2CC5430C-7306-4CA6-B2F9-76144A6D30F7Q36145336-68122906-9653-4CAB-AAE1-C8755764377EQ36149174-21536F0A-7270-44CA-B0F2-0E1AC0499702Q36288383-6DE7D0E3-D860-41AD-AA97-CD3FEA0ECC2DQ36951509-C2197522-12F6-4B1C-99A5-46F4F75B69FBQ37029480-AEE72E8A-B3EB-4451-A668-9C0746B01CAAQ37210270-15CBCB15-0202-484F-A101-744A77123E01Q37290241-73E04B0F-1338-43FA-9A68-B11E20A422B0Q37351687-E59B3B65-2B21-4550-ADB3-B9789706F91DQ37442303-4666E244-095F-4DA8-888B-6C428B1975C4Q38158190-74F78395-A3CD-4DA8-99E9-921336E79AFCQ45958278-2A880CD1-AF15-4EA4-9F09-071EE4EE4C6EQ46434322-D09550CA-CD86-4E9C-B116-00682564FF93Q49116791-7BBB208A-0342-4539-BBA4-1D92A6028DCEQ50777040-11F08551-B158-445D-BEDA-D559D1E6469DQ50896118-834AD50D-5FC1-49C2-B1E5-B7378436A581Q54959720-199AAB57-BBDE-49E6-AF37-B128B8FBB220Q55042938-677D192B-2C62-459B-97E8-F10B9F427ABEQ56832278-1D769A01-E864-42B7-AACD-35AC8DB7CDF2Q57986556-0490576B-70A5-4EC9-9B83-027D8579766D
P2860
Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH)
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Blood cannabinoids. II. Models ...... tetrahydrocannabinol (THCCOOH)
@ast
Blood cannabinoids. II. Models ...... tetrahydrocannabinol (THCCOOH)
@en
Blood cannabinoids. II. Models ...... f delta 9-tetrahydrocannabinol
@nl
type
label
Blood cannabinoids. II. Models ...... tetrahydrocannabinol (THCCOOH)
@ast
Blood cannabinoids. II. Models ...... tetrahydrocannabinol (THCCOOH)
@en
Blood cannabinoids. II. Models ...... f delta 9-tetrahydrocannabinol
@nl
prefLabel
Blood cannabinoids. II. Models ...... tetrahydrocannabinol (THCCOOH)
@ast
Blood cannabinoids. II. Models ...... tetrahydrocannabinol (THCCOOH)
@en
Blood cannabinoids. II. Models ...... f delta 9-tetrahydrocannabinol
@nl
P2093
P356
P1476
Blood cannabinoids. II. Models ...... tetrahydrocannabinol (THCCOOH)
@en
P2093
Henningfield JE
Huestis MA
P304
P356
10.1093/JAT/16.5.283
P577
1992-09-01T00:00:00Z